CAMP4 THERAPEUTICS CORP (CAMP) — insider trading
Health Care · NASDAQ
CAMP4 THERAPEUTICS CORP (CAMP) has 11 reported SEC Form 4 insider transactions in our data (latest 2026-06-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Nashat Amir | Director, 10% owner | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Stewart Murray | Director | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Holtzman Steven H | Director | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Schwab Andrew J. | Director, 10% owner | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Young Richard A | Director | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-06-10 | WILLIAMS DOUGLAS E | Director | Grant / award / vesting (derivative) | 28,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | MacLean Michael F | Director | Grant / award / vesting (derivative) | 56,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Mandel-Brehm Josh | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 580,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Gold Kelly | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 215,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Maricich Yuri | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 215,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Tardiff Daniel | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 170,000 | $0.00 | $0 | Form 4 |
Ask the chat about CAMP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CAMP4 THERAPEUTICS CORP (CAMP).
Last updated 2026-06-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.